Gyre Therapeutics

GYRE

Market cap $685M

Overview Fund Activity

7.54 USD

-0.05

0.66%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

7.54

0.00

0%

1 day

-0.66%

5 days

-8.38%

1 month

-3.95%

3 months

-6.8%

6 months

-38.6%

Year to date

-37.17%

1 year

-46.3%

5 years

-79.23%

10 years

-99.14%

About: Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Employees: 574

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

213% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 8

24% more capital invested

Capital invested by funds: $20.1M [Q1] → $25.1M (+$4.92M) [Q2]

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

2% more funds holding

Funds holding: 46 [Q1] → 47 (+1) [Q2]

0.6% more ownership

Funds ownership: 3.04% [Q1] → 3.64% (+0.6%) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$18

139% upside

Avg. target

$18

139% upside

High target

$18

139% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Matthew Keller

$18

Buy

Initiated

26 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about GYRE published over the past 30 days

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that management will present at the H.C.

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

The global biopharmaceutical landscape is rapidly evolving, driven by innovations targeting complex diseases like organ fibrosis and liver conditions. As companies push the boundaries of medical science, new therapies are emerging that promise to transform patient care and redefine market leadership in these critical areas.

Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced the appointment of Dan Weng, M.D., to its Board of Directors (the “Board”) effective August 18, 2025.

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive Chairman, appointed interim CEO as Dr. Han Ying transitions to scientific leadership role Revenue of $26.8 million and $48.8 million for the three and six months ended June 30, 2025, respectively GAAP basic EPS: $0.00 and $0.04 for the three and six months ended June 30, 2025, respectively Pivotal Phase 3 trial of Hydronidone (F351) in CHB-associated liver fibrosis demonstrated statistically significant fibrosis regression after 52 weeks of treatment; Phase 2 trial in the United States evaluating Hydronidone for the treatment of MASH-associated liver fibrosis expected to initiate in 2H 2025, pending regulatory approval Successfully launched Etorel (nintedanib ethanesulfonate soft capsules) in the PRC for the treatment of SSc-ILD and PF-ILD Announced NMPA approval for clinical trial evaluating pirfenidone capsules in oncology-related pulmonary complications with Phase 2/3 trial anticipated in 2H 2025 First volunteer dosed in Phase 1 clinical trial of F230 for treatment of PAH SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced financial results for the second quarter ended June 30, 2025 and provided a business and leadership update. Dr. Han Ying has stepped down as Chief Executive Officer and will transition into the role of Senior Vice President, Science and will oversee research and discovery activities to support Gyre's fibrosis focused pipeline.

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A (“ETA”) receptor antagonist, for the treatment of pulmonary arterial hypertension (“PAH”). This milestone marks Gyre's entry into the PAH field, a rare, progressive, and high-mortality cardiovascular condition with limited treatment options.

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that it closed its previously announced underwritten public offering of 2,555,555 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 333,333 shares, at a public offering price of $9.00 per share, less the underwriting discount. The gross proceeds of the offering to Gyre, before deducting underwriting discounts and commissions and other offering expenses payable by Gyre, were approximately $23.0 million.

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. In addition, Gyre has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 333,333 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Gyre is expected to grant the underwriters of the offering an option for a period of 30 days to purchase additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs.

Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03 Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B (“CHB”)-associated liver fibrosis; currently reviewing data and on track to report topline results in Q2 2025 Received IND approval from China's National Medical Products Administration (“NMPA”) for a new indication of pirfenidone to treat radiation-induced lung injury (“RILI”), with or without immune-related pneumonitis (“CIP”), marking Gyre's first entry into oncology supportive care space Initiated commercialization of avatrombopag in China in March 2025, building a strategic presence with liver disease specialists Nintedanib remains on track for commercialization in May 2025, expanding IPF treatment options across our physician network $51.3 million in cash, cash equivalents, and short and long-term deposits as of March 31, 2025 SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced financial results for the first quarter ended March 31, 2025 and provided a business update. “This quarter marked a meaningful step forward in expanding our market presence, particularly in the liver space,” said Han Ying, Ph.D.

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

See News Rankings

Charts implemented using Lightweight Charts™